各位朋友好欢迎参加江苏药业2024年度业绩说明会今天由我代表公司董事会及管理层为大家解读公司2024年度的经营情况衷心感谢各位投资人合作伙伴及社会各界对公司的关注与支持在介绍开始之前先做一下几点声明 本次业绩说明会展示的内容涉及一些前瞻性的描述这些描述具有一定的不确定性不构成对投资者的业绩承诺敬请投资者对此保持风险意识为全面了解公司的经营成果、财务状况及未来发展规划投资者可在商交所网站查阅公司2024年年度报告 本次业绩说明会主要分为业绩回顾经营解读及投资者问答三个部分首先我对公司的经营业绩进行简单介绍2024年在一概持续增化集产体制扩面加速医疗防腐持续加压数字化技术变革提速等多方面因素影响下 医药行业呈现整体沉压局部崩坏的发展态势民众市场增速持续惶惶院内市场预计出现下滑而线上市场则保持了快速增长市场态势的演变为公司的发展带来了机遇与挑战并存 2024年是贯彻俄罗斯党的二十大精神 承上启下之年同时也是深入实施十四五规划的攻坚之年公司坚持以习近平新时代中国特色社会主义思想为指导面对行业变化和外部挑战保持战略地理 把握战略主动 砥砺前行 提高核心竞争力 加强研发投入加快数字升级创新突破打造新制生产力推动公司高指标 ...

Summary of the Conference Call for Jiangzhong Pharmaceutical Company Overview - Jiangzhong Pharmaceutical is a leading Chinese OTC (over-the-counter) pharmaceutical company, known for its well-established brands such as "Jiangzhong" and "Chuyuan" [10][24]. Key Financial Performance - **2024 Revenue**: 4.44 billion RMB, a decrease of 2.6% year-on-year [1] - **Net Profit**: 790 million RMB, an increase of 9.7% year-on-year, aligning with previous forecasts [1] - **Q4 2024 Revenue**: 1.31 billion RMB, a decrease of 0.8% year-on-year [1] - **Q4 2024 Net Profit**: 140 million RMB, an increase of 11% year-on-year [1] - **Dividend**: Total cash dividend of 750 million RMB, resulting in a 96% payout ratio and a 5.4% dividend yield [1] Business Segment Performance - **OTC Business**: Revenue increased by 7% year-on-year, impacted by a high base in the first half of the year [2] - **Prescription Drugs**: Revenue decreased by 3.5% year-on-year, affected by centralized procurement policies [2] - **Health Products**: Revenue saw a significant decline of 47.3% year-on-year due to business restructuring [2] - **Gross Margin**: Overall gross margin decreased by 0.06 percentage points to 64.0% [2] - **OTC/Health Products Gross Margin**: Increased by 1 percentage point to 72.7% and 0.6 percentage points to 37.7%, respectively [2] - **Prescription Drugs Gross Margin**: Decreased by 17.5 percentage points to 39.3% [2] - **Expenses**: Sales expenses decreased by 8.9%, while management expenses increased by 3.6% [2] Future Outlook - The company will hold a live earnings release conference on March 21 in Nanchang [3]. Valuation and Investment Rating - **Target Price**: 31.00 RMB, maintaining a "Buy" rating based on the SOTP (Sum of the Parts) valuation method [4][11]. - **Current Stock Price**: 21.93 RMB as of March 19, 2025 [5][24]. - **Market Capitalization**: 13.8 billion RMB (approximately 1.91 billion USD) [5]. Risk Factors - Key risks include: - Underperformance in OTC product sales [11] - Slower-than-expected progress in mergers and acquisitions [11] - Growth and margin improvements in the health business post-restructuring may not meet expectations [11] - Price volatility of key raw materials, particularly Taizishen [11] Additional Insights - The company has a projected stock price increase of 41.4% and a forecasted dividend yield of 3.9%, leading to an expected total return of 45.2% [9]. - The stock is rated as "Buy" with a significant upside potential compared to the market return expectations [19]. This summary encapsulates the essential financial metrics, business performance, future outlook, and investment considerations for Jiangzhong Pharmaceutical as discussed in the conference call.